Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
News NHS to fund Pfizer's Bosulif and Lilly's Alimta NICE is reviewing drugs from old Cancer Drugs Fund.
Views & Analysis What doctors say about changes to the Cancer Drugs Fund Assessing HCPs’ social media comments about the new approach to cancer drug funding.
News Decision to axe Afinitor 'confirms worst fears’ for Cancer D... NICE reviewing 'legacy drugs' to free up CDF funds
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
